FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA approves rivanetin as the first-line treatment for lung cancer.

2.

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

3.

With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.

4.

Discovery of estrogen receptor 'switches' may aid breast cancer treatment

5.

'Significant Milestone' for Radionuclide Therapy in Refractory Meningioma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot